Sun Pharma inks licensing pact with AstraZeneca to introduce products in China

Sun Pharma inks licensing pact with AstraZeneca to introduce products in China This comes after AstraZeneca said it was launching a new fund with China International Capital Corp to invest $1 billion in China#39;s healthcare sector, as it expands its research work in the country.

No comments:

Post a Comment